New Experimental Pill Significantly Extends Survival for Pancreatic Cancer Patients

Kathmandu. Researchers have said that a new experimental pill developed targeting late-stage pancreatic cancer patients has significantly extended the patients' lifespan. This achievement is seen as a major breakthrough in the treatment of pancreatic cancer, considered one of the deadliest cancers in the world. Dr. Zev Weinberg of the University of California, Los Angeles, who led the study, said, 'It does not completely cure cancer, but it is a very big achievement.' The new drug is called Daraxanrasib. It works by inactivating the mutated protein that causes tumor growth in more than 90 percent of pancreatic cancer patients. This target has not been effectively treated for decades. The study involved 500 patients whose cancer had spread to other parts of the body and whose previous treatment had stopped working. They were randomly divided into two groups, with one group receiving Daraxanrasib and the other receiving additional chemotherapy. According to the results, patients who took Daraxanrasib lived an average of 13.2 months. On the other hand, the average lifespan of patients who received only chemotherapy was 6.7 months. 'Although this improvement may seem small, it is the first drug to show clearly better results than chemotherapy,' said Dr. Weinberg. Dr. Rachana Sharaf of Arizona Cancer Center, who was not involved in the study, said she was emotional seeing the results. She said, 'As someone who has been treating pancreatic cancer patients for 16 years, I actually started crying when I saw the study results for the first time.' According to her, many patients continued to use the drug for a long time as it provided long-term and meaningful benefits. Improved Quality of Life Although the pill's effect diminishes over time, researchers have said that it has shrunk tumors, reduced pain, and improved quality of life. Many patients have continued to take the drug even after the study results were released. Therefore, it is estimated that the difference in lifespan may increase further in the coming days. Dr. Brian Wolpin presented the study results at the American Society of Clinical Oncology conference held in Chicago on Sunday. He said, 'This drug should become the new standard of care for metastatic pancreatic cancer whose previous treatment has stopped working.' According to him, studies will also be conducted to see if it can be used in the early stages of the disease. There is a possibility that more patients may become eligible for surgery if the tumor shrinks. This study was financially supported by the drug manufacturer Revolution Medicines. The US Food and Drug Administration (FDA) plans to expedite the drug's approval process. It has also allowed the drug to be made available through an expanded access program to patients who meet certain criteria. Another reason this drug has come into the spotlight is former US Senator Ben Sasse. He said on the television program 60 Minutes that his pain had decreased after taking this drug. Why is Pancreatic Cancer So Deadly? Pancreatic cancer is considered one of the deadliest cancers in the world. The main reason for this is that the disease is extremely difficult to detect in its early stages. In most cases, it is detected only after it has spread to other organs. According to the American Cancer Society, an estimated 67,000 new patients will be added in the US this year, and more than 52,000 people are expected to die from this disease. The overall five-year survival rate for this disease is only 13 percent. How Does the Drug Work? This drug targets mutations in the RAS gene family, which controls cell growth. Specifically, the KRAS mutation is considered the main driver of pancreatic cancer. However, due to the structure of the mutated KRAS protein, it is difficult for drugs to bind to it, making it a target that has been difficult to treat with drugs for a long time. Daraxanrasib, on the other hand, acts like a type of molecular glue and binds to various KRAS subtypes. Andrew Coveler of Fred Hutchinson Cancer Center called this research the beginning of a potential new era in pancreatic cancer treatment. He said, 'This drug works in a completely different way.' Researchers say that other drugs targeting KRAS are also under development. Additionally, early-stage studies are underway on vaccines that train the immune system to prevent cancer from returning after surgery. If future trials are also successful, Daraxanrasib could become one of the biggest breakthroughs in pancreatic cancer treatment in decades.